Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | TP53 | P04637 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | TLR2 | O60603 | 1/20 | 0.55 |
| ▸ | ERN1 | O75460 | 1/20 | 0.55 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.55 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Syringol SCHEMBL156388 | 0.92 | KDM4E (0.80) | KDM4EMAPTTP53LMNACYP3A4 | |
| Syringol SCHEMBL8986496 | 0.90 | KDM4E (0.76) | KDM4EMAPTTP53LMNACYP3A4 | |
| Syringol SCHEMBL7610366 | 0.90 | KDM4E (0.76) | KDM4EMAPTTP53LMNACYP3A4 | |
| Syringol SCHEMBL6049240 | 0.90 | KDM4E (0.76) | KDM4EMAPTTP53LMNACYP3A4 | |
| Syringol SCHEMBL28092678 | 0.85 | KDM4E (0.70) | KDM4EMAPTTP53LMNACYP3A4 | |
| Syringol SCHEMBL20564590 | 0.85 | KDM4E (0.70) | KDM4EMAPTTP53LMNACYP3A4 | |
| Syringol SCHEMBL28128050 | 0.85 | KDM4E (0.70) | KDM4EMAPTTP53LMNACYP3A4 | |
| Syringol SCHEMBL27708099 | 0.85 | KDM4E (0.70) | KDM4EMAPTTP53LMNACYP3A4 | |
| 3-Methoxycatechol SCHEMBL29477155 | 0.82 | TP53 (1.00) | KDM4EMAPTTP53LMNACYP3A4 | |
| 3-Methoxycatechol SCHEMBL67332 | 0.82 | TP53 (1.00) | KDM4EMAPTTP53LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130473-A1 | COMPOUNDS | HUMMERSONE MARC GEOFFREY | 2010-05-27 | — | — | US | disclosed |
| US-7504397-B2 | mTOR inhibitor compounds | KUDOS PHARMACEUTICALS LTD. (GB) | 2009-03-17 | — | — | US | disclosed |
| EP-1877388-A2 | HYDRAZINOMETHYL, HYDRAZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS | Kudos Pharmaceuticals Ltd (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-20060199804-A1 | Compounds | KUDOS PHARMACEUTICALS LTD (GB) | 2006-09-07 | — | — | US | disclosed |
| WO-2006090167-A2 | HYDRAZINOMETHYL, HYDR ZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199804-A1 | Compounds | CA4, CA6, CYP2B6 | KDM4E 2128/4885MAPT 4672/4885TP53 2523/4885 |
| US-20100130473-A1 | COMPOUNDS | CA6, CYP2B6, CA4 | KDM4E 2214/4885MAPT 4601/4885TP53 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.